BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, March 7, 2026
Breaking News: BioWorld Science 2025 Year in Review
See today's BioWorld Science
Home
» China’s NMPA clears China Medical System’s CMS-D008 for clinic
To read the full story,
subscribe
or
sign in
.
Endocrine/metabolic
China’s NMPA clears China Medical System’s CMS-D008 for clinic
March 6, 2026
No Comments
China Medical System Holdings Ltd. has received clinical trial approval from China’s National Medical Products Administration (NMPA) for CMS-D008 injection for overweight or obese individuals.
BioWorld Science
Regulatory
Endocrine/metabolic
RNAi
China
NMPA